Navicixizumab is under clinical development by OncXerna Therapeutics and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According to GlobalData, Phase II drugs for Adenocarcinoma Of The Gastroesophageal Junction have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Navicixizumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Navicixizumab (OMP-305B83) is under development for the treatment of platinum-resistant ovarian cancer, primary peritoneal, fallopian tube cancer and refractory solid tumors including breast cancer, pancreatic cancer, uterus cancer, lung cancer, endometrial cancer, gastric cancer, adenocarcinoma of the gastroesophageal junction, triple-negative breast cancer (TNBC) and uterine carcinosarcoma. It is administered intravenously. It is an anti-DLL4/VEGF bi-specific antibody. OMP-305B83 is a monoclonal antibody that targets both DLL4 and vascular endothelial growth factor. It is developed utilizing OncoMed's BiMAb technology platform. It was under development for solid tumors including metastatic colorectal cancer and uterine carcinosarcoma.
OncXerna Therapeutics overview
OncXerna Therapeutics is engaged in the development of state-of-the-art precision medicine for cancer patients and is also involved in discovering the dominant biology related characteristics in a person’s cancer at the RNA level to advance more meaningful treatments for more cancer patients. OncXerna Therapeutics is headquartered in Massachusetts, the US.
For a complete picture of Navicixizumab’s drug-specific PTSR and LoA scores, buy the report here.